Published in Neuroepidemiology on January 01, 1998
Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ (2001) 5.40
Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag (2008) 2.13
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem (2008) 2.00
Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler Thromb Vasc Biol (2008) 1.88
Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.81
The role of nutrition in Alzheimer's disease: epidemiological evidence. Eur J Neurol (2009) 1.71
Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ (2008) 1.70
The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology (2010) 1.64
The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm (2010) 1.59
Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord (2009) 1.58
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension (2009) 1.46
Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol (2011) 1.42
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics (2008) 1.36
Association of statin use with cognitive decline in elderly African Americans. Neurology (2007) 1.34
Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res Ther (2012) 1.30
Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med (2010) 1.28
Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J Neurosci (2009) 1.27
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging (2010) 1.25
The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation (2006) 1.25
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem (2008) 1.24
Promoting successful cognitive aging: a comprehensive review. J Alzheimers Dis (2010) 1.19
Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest (2003) 1.19
Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol (2011) 1.17
Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med (2008) 1.16
Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol (2003) 1.14
Lipid-lowering drugs. Cell Mol Life Sci (2006) 1.14
The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci (2009) 1.13
Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance. Prog Neurobiol (2014) 1.13
Association between APOE epsilon4 allele and vascular dementia: The Cache County study. Dement Geriatr Cogn Disord (2010) 1.10
Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. Curr Psychiatry Rev (2009) 1.09
Glutathione and mitochondria. Front Pharmacol (2014) 1.08
Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement (2011) 1.08
Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology (2006) 1.06
The effects of cholesterol on learning and memory. Neurosci Biobehav Rev (2010) 1.05
Serum lipids and memory in a population based cohort of middle age women. J Neurol Neurosurg Psychiatry (2003) 1.05
Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimer Dis Assoc Disord (2009) 1.02
Dietary fat composition and dementia risk. Neurobiol Aging (2014) 1.01
Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis (2010) 1.01
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol (2004) 0.98
Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage (2008) 0.96
Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death. Biochim Biophys Acta (2010) 0.95
Perimenopause and cognition. Obstet Gynecol Clin North Am (2011) 0.94
High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer's disease patients. Mol Med (2009) 0.94
Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med (2015) 0.93
Age-related influence of the HDL receptor SR-BI on synaptic plasticity and cognition. Neurobiol Aging (2007) 0.93
Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol (2007) 0.93
Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study. J Neurol (2011) 0.92
Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis (2012) 0.90
Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med (2010) 0.89
Midlife predictors of Alzheimer's disease. Maturitas (2009) 0.89
High dietary cholesterol facilitates classical conditioning of the rabbit's nictitating membrane response. Nutr Neurosci (2007) 0.88
Prevalence of Alzheimer's dementia and its risk factors in community-dwelling elderly koreans. Psychiatry Investig (2008) 0.88
Alcohol effects on cognitive change in middle-aged and older adults. Aging Ment Health (2012) 0.88
Novel N-terminal cleavage of APP precludes Abeta generation in ACAT-defective AC29 cells. J Mol Neurosci (2008) 0.87
Monounsaturated, trans, and saturated Fatty acids and cognitive decline in women. J Am Geriatr Soc (2011) 0.87
Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res (2006) 0.87
Alzheimer's disease--a dysfunction in cholesterol and lipid metabolism. Cell Mol Neurobiol (2005) 0.87
Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2002) 0.86
Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: is it contributing to higher risk of cognitive decline and coronary heart disease? Nutrients (2014) 0.86
Risk factors for dementia in the epidemiological study of Munguialde County (Basque Country-Spain). BMC Neurol (2008) 0.86
Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta (2011) 0.86
Cholesterol in mild cognitive impairment and Alzheimer's disease in a birth cohort over 14 years. Eur Arch Psychiatry Clin Neurosci (2013) 0.85
Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J Alzheimers Dis (2012) 0.85
Cognitive impairment and Alzheimer's disease: Links with oxidative stress and cholesterol metabolism. Neuropsychiatr Dis Treat (2008) 0.85
Mitochondria, cholesterol and amyloid beta peptide: a dangerous trio in Alzheimer disease. J Bioenerg Biomembr (2009) 0.85
Gene-environment interaction research and transgenic mouse models of Alzheimer's disease. Int J Alzheimers Dis (2010) 0.85
Influence of peroxisome proliferator-activated receptor gamma gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients. J Neural Transm (Vienna) (2005) 0.85
Dyslipidemia and the risk of Alzheimer's disease. Curr Atheroscler Rep (2013) 0.85
Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther (2012) 0.85
Midlife cardiovascular risk factors and late cognitive impairment. Eur J Epidemiol (2013) 0.84
Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease. BMC Geriatr (2001) 0.84
The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset. Int Rev Psychiatry (2013) 0.84
Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease. Dement Geriatr Cogn Disord (2008) 0.84
Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. Curr Gerontol Geriatr Res (2010) 0.83
Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. J Gerontol A Biol Sci Med Sci (2010) 0.83
Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I? Am J Epidemiol (2007) 0.83
Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats. BMC Pharmacol (2008) 0.83
Deconstructing racial differences: the effects of quality of education and cerebrovascular risk factors. J Gerontol B Psychol Sci Soc Sci (2014) 0.83
Decreased serum lipids in patients with probable Alzheimer's disease. Bosn J Basic Med Sci (2009) 0.82
Non-pharmacologic prevention of Alzheimer's disease: nutritional and life-style risk factors. J Neural Transm (Vienna) (2007) 0.82
Total cholesterol and the risk of Parkinson's disease: a review for some new findings. Parkinsons Dis (2009) 0.82
Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.82
Role of copper and cholesterol association in the neurodegenerative process. Int J Alzheimers Dis (2013) 0.82
Simvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro. Int J Alzheimers Dis (2012) 0.82
Baseline serum cholesterol is selectively associated with motor speed and not rates of cognitive decline: the Women's Health and Aging Study II. J Gerontol A Biol Sci Med Sci (2008) 0.82
Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome. Neurosci Lett (2007) 0.81
HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. Front Pharmacol (2014) 0.81
On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks. Alzheimer Dis Assoc Disord (2009) 0.81
Links between copper and cholesterol in Alzheimer's disease. Front Physiol (2013) 0.81
Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci (2014) 0.80
Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors. J Neural Transm (Vienna) (2011) 0.80
Role of vitamin B(12), folate, and thyroid stimulating hormone in dementia: A hospital-based study in north Indian population. Ann Indian Acad Neurol (2010) 0.79
Therapeutic approaches to age-associated neurocognitive disorders. Dialogues Clin Neurosci (2001) 0.79
Diet and Alzheimer's disease: what the evidence shows. MedGenMed (2004) 0.78
A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. Neuropsychiatr Dis Treat (2013) 0.78
Hypertension and diabetes as risk factors for dementia: A secondary post-hoc analysis from north-west India. Ann Indian Acad Neurol (2015) 0.78
The relationship between cholesterol and cognitive function is homocysteine-dependent. Clin Interv Aging (2014) 0.77
Circulating biomarkers that predict incident dementia. Alzheimers Res Ther (2014) 0.77
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Haplotype tagging for the identification of common disease genes. Nat Genet (2001) 11.27
Should there be a moratorium on the use of cholesterol lowering drugs? BMJ (1992) 9.85
High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation (1992) 7.11
Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet (2000) 6.94
Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 6.20
Preventing non-insulin-dependent diabetes. Diabetes (1995) 6.16
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Confounding and effect modification in the short-term effects of ambient particles on total mortality: results from 29 European cities within the APHEA2 project. Epidemiology (2001) 5.80
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ (2001) 5.40
Controlled, randomised trial of the effect of dietary fat on blood pressure. Lancet (1983) 5.31
Early growth and coronary heart disease in later life: longitudinal study. BMJ (2001) 5.25
Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia (1992) 5.25
Catch-up growth in childhood and death from coronary heart disease: longitudinal study. BMJ (1999) 5.17
Worldwide increase in incidence of Type I diabetes--the analysis of the data on published incidence trends. Diabetologia (1999) 5.11
Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother (1993) 4.83
Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care (2000) 4.62
Resistance to erythromycin in group A streptococci. N Engl J Med (1992) 4.42
Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet (2001) 4.39
The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Annu Rev Public Health (1985) 4.30
The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med (2000) 4.29
Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol (1996) 4.23
Change in risk factors for coronary heart disease during 10 years of a community intervention programme (North Karelia project). Br Med J (Clin Res Ed) (1983) 4.00
Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care (1998) 3.99
The genetically isolated populations of Finland and sardinia may not be a panacea for linkage disequilibrium mapping of common disease genes. Nat Genet (2000) 3.92
Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ (1994) 3.92
Changes in coronary risk factors during comprehensive five-year community programme to control cardiovascular diseases (North Karelia project). Br Med J (1979) 3.75
Mother's weight in pregnancy and coronary heart disease in a cohort of Finnish men: follow up study. BMJ (1997) 3.63
Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology (2001) 3.56
Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med (1995) 3.54
Non-eosinophilic asthma: importance and possible mechanisms. Thorax (2002) 3.53
A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group. Diabetologia (1993) 3.35
A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15
The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med (2000) 3.10
Educational level, relative body weight, and changes in their association over 10 years: an international perspective from the WHO MONICA Project. Am J Public Health (2000) 3.08
The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia (2009) 3.05
How much asthma is really attributable to atopy? Thorax (1999) 3.04
Symptoms of chronic bronchitis and the risk of coronary disease. Lancet (1996) 3.03
Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation (1995) 2.99
Theory and action for health promotion illustrations from the North Karelia Project. Am J Public Health (1982) 2.95
Twenty-year trends in coronary risk factors in north Karelia and in other areas of Finland. Int J Epidemiol (1994) 2.91
Social class, health behaviour, and mortality among men and women in eastern Finland. BMJ (1995) 2.89
Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis (1991) 2.83
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ (1995) 2.80
Decline in mortality from coronary heart disease in Finland from 1969 to 1979. Br Med J (Clin Res Ed) (1983) 2.80
Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study. BMJ (1999) 2.78
Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation (1999) 2.78
Perceived health status and morbidity and mortality: evidence from the Kuopio ischaemic heart disease risk factor study. Int J Epidemiol (1996) 2.73
Changes in smoking, serum cholesterol and blood pressure levels during a community-based cardiovascular disease prevention program--the North Karelia Project. Am J Epidemiol (1981) 2.72
Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care (1998) 2.70
Early adiposity rebound in childhood and risk of Type 2 diabetes in adult life. Diabetologia (2003) 2.60
Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens (1987) 2.59
Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. Lancet (1978) 2.56
Blood group M specific haemagglutinin in pyelonephritogenic Escherichia coli. Lancet (1982) 2.56
Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia (1999) 2.51
Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J (2002) 2.46
Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care (1995) 2.44
Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia (2011) 2.43
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care (1999) 2.41
Age, body mass index and Type 2 diabetes-associations modified by ethnicity. Diabetologia (2003) 2.37
Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J (2002) 2.31
Body mass index and the risk of Parkinson disease. Neurology (2006) 2.28
Effects of supporting community-living demented patients and their caregivers: a randomized trial. J Am Geriatr Soc (2001) 2.28
Diagnostic criteria and quality control of the registration of stroke events in the MONICA project. Acta Med Scand Suppl (1988) 2.26
Education and dementia: what lies behind the association? Neurology (2007) 2.26
A gene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population. Childhood Diabetes in Finland (DiMe) Study Group. Diabetologia (1994) 2.25
Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax (2000) 2.25
Diet, nutrition and the prevention of type 2 diabetes. Public Health Nutr (2004) 2.25
Urban air pollution, and asthma and COPD hospital emergency room visits. Thorax (2008) 2.23
Decline in cardiovascular mortality in North Karelia and other parts of Finland. Br Med J (Clin Res Ed) (1986) 2.22
Diabetes, prediabetes and cancer mortality. Diabetologia (2010) 2.22
Physical activity and risk of myocardial infarction, cerebral stroke and death: a longitudinal study in Eastern Finland. Am J Epidemiol (1982) 2.20
Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. Neurology (2011) 2.19
Telecommunication and international health research. Am J Epidemiol (1988) 2.19